The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
Clinical trial NCT03152084 · TERMINATED
Trial details
- NCT number
- NCT03152084
- Sponsor
- AstraZeneca
- Status
- TERMINATED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2017-07-12
- Primary completion
- 2020-03-20
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.